| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
92,610,000 |
| Market
Cap: |
2.13(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$15.07 - $31.94 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Rocket Pharmaceuticals is a clinical-stage, multi-platform biotechnology company focused on the development of gene therapies for rare and devastating pediatric diseases. Co. has three clinical-stage ex vivo lentiviral vector. These include programs for Fanconi Anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I, a genetic disorder that causes the immune system to malfunction, and Pyruvate Kinase Deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,355,932 |
| Total Buy Value |
$0 |
$0 |
$0 |
$19,999,997 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
418,173 |
438,811 |
467,219 |
487,632 |
| Total Sell Value |
$11,574,225 |
$12,042,227 |
$12,602,151 |
$12,990,263 |
| Total People Sold |
7 |
7 |
7 |
8 |
| Total Sell Transactions |
12 |
14 |
24 |
29 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Medimmune Ventures, Inc. |
10% Owner |
– – • |
2015-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
1,312,327 |
1,501,239 |
|
- |
|
| Kantesaria Devang |
10% Owner |
– – • |
2015-02-23 |
4 |
B |
$6.00 |
$4,884,996 |
I/I |
814,166 |
3,243,709 |
1.5 |
- |
|
| Kantesaria Devang |
10% Owner |
– – • |
2015-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
2,429,543 |
2,429,543 |
|
- |
|
| Devon Park Associates, Llc |
10% Owner |
– – • |
2015-02-23 |
4 |
B |
$6.00 |
$4,884,996 |
I/I |
814,166 |
3,243,709 |
1.5 |
- |
|
| Devon Park Associates, Llc |
10% Owner |
– – • |
2015-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
2,429,543 |
2,429,543 |
|
- |
|
| Leschly Mark |
10% Owner |
– – • |
2015-02-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
233,036 |
|
- |
|
| Pitango G.c. Capital Holdings Ltd. |
10% Owner |
– – • |
2015-02-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
194,642 |
|
- |
|
| Karabelas Argeris N |
Director |
– • • |
2015-02-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
215,102 |
|
- |
|
| Medimmune Ventures, Inc. |
10% Owner |
– – • |
2015-02-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
188,912 |
|
- |
|
| Care Capital Offshore Investments Iii Lp |
10% Owner |
– – • |
2015-02-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
215,102 |
|
- |
|
135 Records found
|
|
Page 6 of 6 |
|
|
0.38 (1.63%) 
